Literature DB >> 31989654

Real-time measurement of E2: ERα transcriptional activity in living cells.

Manuela Cipolletti1, Stefano Leone1, Stefania Bartoloni1, Claudia Busonero1, Filippo Acconcia1.   

Abstract

Kinetic analyses of diverse physiological processes have the potential to unveil new aspects of the molecular regulation of cell biology at temporal levels. 17β-estradiol (E2) regulates diverse physiological effects by binding to the estrogen receptor α (ERα), which primarily works as a transcription factor. Although many molecular details of the modulation of ERα transcriptional activity have been discovered including the impact of receptor plasma membrane localization and its relative E2-evoked signaling, the knowledge of real-time ERα transcriptional dynamics in living cells is lacking. Here, we report the generation of MCF-7 and HeLa cells stably expressing a modified luciferase under the control of an E2-sensitive promoter, which activity can be continuously monitored in living cells and show that E2 induces a linear increase in ERα transcriptional activity. Ligand-independent (e.g., epidermal growth factor) receptor activation was also detected in a time-dependent manner. Kinetic profiles of ERα transcriptional activity measured in the presence of both receptor antagonists and inhibitors of ERα plasma membrane localization reveal a biphasic dynamic of receptor behavior underlying novel aspects of receptor-regulated transcriptional effects. Finally, analysis of the rate of the dose-dependent E2 induction of ERα transcriptional activity demonstrates that low doses of E2 induce an effect identical to that determined by high concentrations of E2 as a function of the duration of hormone administration. Overall, we present the characterization of sensitive stable cell lines were to study the kinetic of E2 transcriptional signaling and to identify new aspects of ERα function in different physiological or pathophysiological conditions.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  17β-estradiol; breast cancer; estrogen receptor; palmitoylation; transcriptional activity

Mesh:

Substances:

Year:  2020        PMID: 31989654     DOI: 10.1002/jcp.29565

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  7 in total

1.  The role of estrogen in circular RNA and metabonomics in a Neisseria gonorrhoeae infection model.

Authors:  Guiyue Cai; Jin Long; Ruitao Zou; Huizhi Yang; Jiahao Xie; Chunchan Zheng; Xiaoxuan Chen; Shuang Liu; Rongyi Chen
Journal:  Ann Transl Med       Date:  2022-09

2.  Unexpected Impact of a Hepatitis C Virus Inhibitor on 17β-Estradiol Signaling in Breast Cancer.

Authors:  Stefania Bartoloni; Stefano Leone; Filippo Acconcia
Journal:  Int J Mol Sci       Date:  2020-05-12       Impact factor: 5.923

3.  Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ERα expression and proliferation in luminal primary and metastatic breast cancer cells.

Authors:  Sara Pescatori; Stefano Leone; Manuela Cipolletti; Stefania Bartoloni; Alessandra di Masi; Filippo Acconcia
Journal:  J Exp Clin Cancer Res       Date:  2022-04-13

4.  The antiviral drug telaprevir induces cell death by reducing FOXA1 expression in estrogen receptor α (ERα)-positive breast cancer cells.

Authors:  Stefania Bartoloni; Stefano Leone; Sara Pescatori; Manuela Cipolletti; Filippo Acconcia
Journal:  Mol Oncol       Date:  2022-09-03       Impact factor: 7.449

5.  Evaluation of the Sensitivity of Breast Cancer Cell Lines to Cardiac Glycosides Unveils ATP1B3 as a Possible Biomarker for the Personalized Treatment of ERα Expressing Breast Cancers.

Authors:  Filippo Acconcia
Journal:  Int J Mol Sci       Date:  2022-09-21       Impact factor: 6.208

Review 6.  A Tale of Ice and Fire: The Dual Role for 17β-Estradiol in Balancing DNA Damage and Genome Integrity.

Authors:  Sara Pescatori; Francesco Berardinelli; Jacopo Albanesi; Paolo Ascenzi; Maria Marino; Antonio Antoccia; Alessandra di Masi; Filippo Acconcia
Journal:  Cancers (Basel)       Date:  2021-03-30       Impact factor: 6.639

7.  A New Anti-Estrogen Discovery Platform Identifies FDA-Approved Imidazole Anti-Fungal Drugs as Bioactive Compounds against ERα Expressing Breast Cancer Cells.

Authors:  Manuela Cipolletti; Stefania Bartoloni; Claudia Busonero; Martina Parente; Stefano Leone; Filippo Acconcia
Journal:  Int J Mol Sci       Date:  2021-03-13       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.